WO2024047537 - NOVEL PARENTERAL FORMULATIONS OF CANNABIDIOL
National phase entry:
Publication Number
WO/2024/047537
Publication Date
07.03.2024
International Application No.
PCT/IB2023/058549
International Filing Date
30.08.2023
Title **
[English]
NOVEL PARENTERAL FORMULATIONS OF CANNABIDIOL
[French]
NOUVELLES FORMULATIONS PARENTÉRALES DE CANNABIDIOL
Applicants **
LEIUTIS PHARMACEUTICALS LLP
Inventors
KOCHERLAKOTA, Chandrashekhar
BANDA, Nagaraju
NARALA, Arjun
RAMREDDY, Srividya
PULLAGURA, Naga Udaya Sankar
AKULA, Srinath
Priority Data
202241049537
30.08.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
* |
| Recordal of a Change of the Applicant's Name/Address | * |
| Type of Assignment | * |
| Applicant's Legal Status | * |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under | * |
| Patent Delivery | * |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2364 | |
| EPO | Filing, Examination, Granting | 15001 | |
| Japan | Filing, Examination, Granting | 2504 | |
| South Korea | Filing, Examination, Granting | 2833 | |
| USA | Filing, Examination, Granting | 8940 |
Total:
31,642
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to parenteral emulsion formulations of cannabidiol comprising synthetic cannabidiol (CBD), omega 3 components and other pharmaceutically acceptable excipients. The invention further relates to parenteral emulsion formulations comprising synthetic cannabidiol in combination with one or more active agents, omega 3 components, and other pharmaceutically acceptable excipients. The formulations are used to treat acute and chronic pain, inflammatory conditions, hepatic, cardiovascular disorders, respiratory conditions, immune disorders, and CNS disorders.[French]
La présente invention concerne des formulations d'émulsion parentérale de cannabidiol comprenant du cannabidiol synthétique (CBD), des composants oméga 3 et d'autres excipients pharmaceutiquement acceptables. L'invention concerne en outre des formulations d'émulsion parentérale comprenant du cannabidiol synthétique en combinaison avec un ou plusieurs agents actifs, des composants oméga 3 et d'autres excipients pharmaceutiquement acceptables. Les formulations sont utilisées pour traiter une douleur aiguë et chronique, des affections inflammatoires, des troubles hépatiques, cardiovasculaires, des affections respiratoires, des troubles immunitaires et des troubles du SNC.